Non-inferiority RCT in 442 treated adults with advanced HIV: bictegravir-based vs boosted darunavir-based therapy had 48-week virological or clinical events in 22% vs 32% (HR 0.70; non-inferior), and fewer drug-related adverse events; deaths 9 vs 3, unrelated to drugs.
RCTn = 447
Behrens et al. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial